الفهرس 
Abstract English
Increasing the activity and safety of the anti-inflammatory drug betamethasone valerate via niosomalOnly 14 pages are availabe for public view
 |  | from | 277 |  |  |
| | | from | 277 | | |
Abstract
Skin disorders represent 10% of all problems managed in general practice. Corticosteroids are one of the oldest and most effective therapies for skin disorders. Betamethasone-17 valerate is a potent synthetic glucocorticoid used in a variety of allergic and inflammatory skin disorders. It is effective in the treatment of psoriasis and various types of dermatitis. It is very potent and offers a 10-fold higher potency than hydrocortisone where 750 og of Betamethasone is equivalent in anti-inflammatory activity to about 5 mg of prednisolone. Unfortunately, its use is limited due to side effects frequently occurring at both the topical and systemic levels. chronic application of topical corticosteroids generally leads to local side effects such as skin infections, striae, rosacea and skin atrophy. When highly absorbed, systemic adverse effects (e.g., glaucoma, hypertension and hyperglycemia) appear compromising the therapeutic effectiveness and patient adherence. Recently, there has been a lot of interest in developing new drug carriers for corticosteroids which can enhance the drug skin retention and minimize the penetrating amount into systemic circulation upon topical application. Among various vesicular carriers, niosome is selected as a carrier of choice for its superiority over conventional liposomes in terms of cost-effectiveness and stability